A Diagnostic and Therapeutic Agent for Epithelial Cancers
Health Sciences Technologies for Licensing
Researchers at the University of Tennessee have discovered that the odontogenic ameloblastassociated protein (ODAM) can be detected in human epithelial cancers, including those of breast, lung, and gastric origin as well as primary melanoma. The inventors also discovered that ODAMreactive antibodies are present in the serum of patients suffering from these same cancers. The research group of Dan Kestler has generated antibodies that can be used not only as research reagents but also may be developed into diagnostic kits for clinical monitoring of patients with melanoma or breast cancer. An ELISA assay has been developed that has potential for detecting cancer-related proteins in the blood of patients with breast cancer.
- A sensitive diagnostic and prognostic biomarker for human epithelial cancers.
- A specific therapeutic target for human epithelial cancers
- Patent pending